USANA Health Sciences (NYSE:USNA) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

USANA Health Sciences (NYSE:USNA) released its earnings results on Tuesday. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.11), RTT News reports. USANA Health Sciences had a return on equity of 11.26% and a net margin of 6.29%. The firm had revenue of $212.87 million during the quarter, compared to analyst estimates of $218.64 million. During the same quarter last year, the business posted $0.89 EPS. USANA Health Sciences updated its FY 2024 guidance to 2.400-2.550 EPS.

USANA Health Sciences Trading Down 3.2 %

Shares of NYSE USNA traded down $1.43 during midday trading on Thursday, reaching $43.06. 25,658 shares of the stock were exchanged, compared to its average volume of 79,679. The company has a market capitalization of $820.29 million, a P/E ratio of 13.86, a P/E/G ratio of 1.38 and a beta of 0.90. USANA Health Sciences has a 52-week low of $40.51 and a 52-week high of $69.60. The stock has a 50 day moving average price of $46.34 and a 200-day moving average price of $47.09.

Insider Transactions at USANA Health Sciences

In related news, insider Daniel A. Macuga sold 3,791 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total value of $178,707.74. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other USANA Health Sciences news, insider Daniel A. Macuga sold 3,791 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total transaction of $178,707.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Myron W. Wentz sold 13,496 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $45.03, for a total transaction of $607,724.88. Following the completion of the transaction, the insider now owns 7,864,345 shares of the company’s stock, valued at $354,131,455.35. The disclosure for this sale can be found here. Insiders sold a total of 31,591 shares of company stock worth $1,458,098 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on USNA shares. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday. DA Davidson cut their price target on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.